FG-3019 (Pamrevlumab) to show reversal of pulmonary fibrosis in Phase-II study

An investigational drug code named FG-3019 developed by FibroGen Inc. caught headlines recently after FibroGen published results of its recently concluded preliminary Phase-II study. The study was published in the European Respiratory Journal, in an article titled “FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF.” Continue reading

What are the most effective therapies for pulmonary fibrosis?

Idiopathic pulmonary fibrosis (IPF) is a devastating condition where the lung tissues progressively thickens and turn into scar tissues leading to breathlessness and ultimately respiratory failure and death. The treatment for IPF has changed drastically over the past few years. Traditionally, IPF were treated with high doses of corticosteroids in combination with other medications to suppress the immune system. New medications, pirfenidone and nintedanib, have made it possible to slow down the progression of the condition. Other supplemental agents such as N-acetylcysteine (NAC) has often been used as an adjunct therapy in pulmonary fibrosis. We often get asked about what the effectiveness of different therapies in pulmonary fibrosis. Continue reading

Living with Idiopathic Pulmonary Fibrosis

When lung tissue gets damaged or scarred over time, it can become difficult to get enough oxygen from the lungs into your bloodstream. The result is a shortage of oxygen to your brain, extremities, and vital organs in a condition called idiopathic pulmonary fibrosis (IPF). The condition commonly affects adults who are middle-aged or older, and unfortunately there is currently no cure, although there are options for treating the disease that can help you live a longer and more comfortable life. Continue reading

What You Might Not Know About Pulmonary Fibrosis

The air you breathe is essential to your long-term health, but for some people it’s difficult to get enough oxygen into your bloodstream. If you suffer from pulmonary fibrosis, you know that it’s a condition that limits the air that can get through your lungs and into your blood because the tissues around and between air sacs in the lungs thicken and scar over time. The shortness of breath and difficulty getting enough oxygen get worse over time, causing significant fatigue.

What you might not know is that the scarring you experience that leads to thickening of tissues over time could actually be caused by several different factors in your environment, such as airborne toxins, lung diseases, radiation, or medical treatments. It can be difficult for healthcare professionals to pinpoint the exact cause, which leads to a diagnosis of idiopathic pulmonary fibrosis (IPF). Continue reading